Martin Babler, Alumis CEO
March 6, 2024 08:00 AM ESTUpdated March 13, 02:18 PM
Financing
R&D

Alu­mis clos­es a $259M Se­ries C to back its TYK2, flirts with talk about an IPO

Max Gelman

Senior Editor

As it pre­pares to launch Phase III stud­ies of its TYK2 in­hibitor, im­munol­o­gy start­up Alu­mis has raised a $259 mil­lion Se­ries C round that will …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

NIH’s fund­ing cut plan pos­es chal­lenges for re­searchers de­spite court halt

Ab­b­Vie pens an­oth­er T cell en­gager deal, this time with Xilio

Bio­gen down­plays ca­pac­i­ty for M&A; Roche’s SMA drug is ap­proved as a tablet

Anap­tys­Bio gets a mid-stage win for PD-1 drug in rheuma­toid arthri­tis

Novo's weight loss drug helps curb some drink­ing habits, small study shows

sponsored

Re­duc­ing risk in drug de­vel­op­ment: The im­por­tance of val­i­dat­ed MRD test­ing in lym­phoid can­cers

A service from the Financial Times